Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1969 1
1970 8
1971 19
1972 21
1973 14
1974 14
1975 7
1976 17
1977 12
1978 7
1979 12
1980 14
1981 14
1982 7
1983 14
1984 7
1985 11
1986 5
1987 2
1988 2
1989 13
1990 10
1991 20
1992 16
1993 16
1994 11
1995 14
1996 28
1997 22
1998 32
1999 38
2000 58
2001 53
2002 39
2003 70
2004 69
2005 67
2006 75
2007 70
2008 90
2009 96
2010 112
2011 93
2012 96
2013 149
2014 132
2015 118
2016 91
2017 69
2018 85
2019 75
2020 16
Text availability
Article attribute
Article type
Publication date

Search Results

1,978 results
Results by year
Filters applied: . Clear all
Page 1
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N, Townsend CM, Parker CE, MacDonald JK. Chande N, et al. Cochrane Database Syst Rev. 2016 Oct 26;10(10):CD000545. doi: 10.1002/14651858.CD000545.pub5. Cochrane Database Syst Rev. 2016. PMID: 27783843 Free PMC article. Review.
OBJECTIVES: The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction of remission in active Crohn's disease. ...AUTHORS' CONCLUSIONS: Azathioprine and 6-mercaptopurine offer no adva …
OBJECTIVES: The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction …
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Chande N, et al. Cochrane Database Syst Rev. 2015 Oct 30;(10):CD000067. doi: 10.1002/14651858.CD000067.pub3. Cochrane Database Syst Rev. 2015. PMID: 26517527 Review.
OBJECTIVES: To assess the efficacy of AZA and 6-MP for maintenance of remission in quiescent Crohn's disease. SEARCH METHODS: We searched MEDLINE, EMBASE, and the Cochrane Library from inception to June 30, 2015. SELECTION CRITERIA: Randomized controlled tria …
OBJECTIVES: To assess the efficacy of AZA and 6-MP for maintenance of remission in quiescent Crohn's disease. SEARCH ME …
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gjuladin-Hellon T, Iheozor-Ejiofor Z, Gordon M, Akobeng AK. Gjuladin-Hellon T, et al. Cochrane Database Syst Rev. 2019 Aug 6;8(8):CD010233. doi: 10.1002/14651858.CD010233.pub3. Cochrane Database Syst Rev. 2019. PMID: 31425621 Free PMC article.
BACKGROUND: Crohn's disease (CD) is a chronic relapsing inflammatory condition and maintenance of remission is a major issue as many patients fail to achieve remission with medical management and require surgical interventions. Purine analogues such as azathioprine …
BACKGROUND: Crohn's disease (CD) is a chronic relapsing inflammatory condition and maintenance of remission is a major issue a …
Crohn's disease management after intestinal resection: a randomised trial.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV. De Cruz P, et al. Lancet. 2015 Apr 11;385(9976):1406-17. doi: 10.1016/S0140-6736(14)61908-5. Epub 2014 Dec 24. Lancet. 2015. PMID: 25542620 Clinical Trial.
BACKGROUND: Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery. This study aimed to identify the optimal strategy to prevent postoperative disease
BACKGROUND: Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience di
Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease.
Garg SK, Velayos FS, Kisiel JB. Garg SK, et al. Gastroenterol Clin North Am. 2017 Sep;46(3):515-529. doi: 10.1016/j.gtc.2017.05.006. Gastroenterol Clin North Am. 2017. PMID: 28838412 Review.
Crohn's disease (CD) is a chronic inflammatory disease that confers a higher risk of cancer than in the general population. New, large, population-based studies in the past decade show that patients with CD are at higher risk of colorectal, small bowel, melan
Crohn's disease (CD) is a chronic inflammatory disease that confers a higher risk of cancer than in the general populat
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Bermejo F, et al. Gastroenterol Hepatol. 2018 Mar;41(3):205-221. doi: 10.1016/j.gastrohep.2017.11.007. Epub 2018 Jan 19. Gastroenterol Hepatol. 2018. PMID: 29357999 Review. English, Spanish.
Thiopurines (azathioprine and mercaptopurine) are widely used in patients with inflammatory bowel disease. In this paper, we review the main indications for their use, as well as practical aspects on efficacy, safety and method of administration. They are mainly use …
Thiopurines (azathioprine and mercaptopurine) are widely used in patients with inflammatory bowel disease. In this paper, we r …
6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.
Actis GC, Pellicano R, Rosina F. Actis GC, et al. Inflamm Allergy Drug Targets. 2015;14(2):133-7. doi: 10.2174/1871528114666160105112915. Inflamm Allergy Drug Targets. 2015. PMID: 26728773 Review.
Thiopurines have been shown to effectively maintain remission of both Crohn's disease (CD) and ulcerative colitis (UC), and to behave as disease modifiers if used for >12 months in UC. ...For the aim of this study we searched our own database and the MedLi …
Thiopurines have been shown to effectively maintain remission of both Crohn's disease (CD) and ulcerative colitis (UC), and to …
Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J, Hamlin J, Dhar A, Nwokolo C, Edwards C, Creed T, Bloom S, Yousif M, Thomas L, Campbell S, Lewis SJ, Sebastian S, Sen S, Lal S, Hawkey C, Murray C, Cummings F, Goh J, Lindsay JO, Arebi N, Potts L, McKinley AJ, Thomson JM, Todd JA, Collie M, Dunlop MG, Mowat A, Gaya DR, Winter J, Naismith GD, Ennis H, Keerie C, Lewis S, Prescott RJ, Kennedy NA, Satsangi J; TOPPIC Study Group. Mowat C, et al. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):273-282. doi: 10.1016/S2468-1253(16)30078-4. Epub 2016 Aug 30. Lancet Gastroenterol Hepatol. 2016. PMID: 28404197 Free PMC article. Clinical Trial.
FINDINGS: Between June 6, 2008, and April 23, 2012, 240 patients with Crohn's disease were randomly assigned: 128 to mercaptopurine and 112 to placebo. ...INTERPRETATION: Mercaptopurine is effective in preventing postoperative clinical recurrenc …
FINDINGS: Between June 6, 2008, and April 23, 2012, 240 patients with Crohn's disease were randomly assigned: 128 to …
Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
Korelitz BI. Korelitz BI. World J Gastroenterol. 2013 May 28;19(20):2979-84. doi: 10.3748/wjg.v19.i20.2979. World J Gastroenterol. 2013. PMID: 23716977 Free PMC article.
The induction of remission was first demonstrated by 6-mercaptopurine (6-MP) with case reports and uncontrolled trials in patients with ulcerative colitis, but its placebo controlled trial for Crohn's disease firmly established its role in induc …
The induction of remission was first demonstrated by 6-mercaptopurine (6-MP) with case reports and uncontrolled trials …
6-thioguanine--efficacy and safety in chronic active Crohn's disease.
Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF. Herrlinger KR, et al. Aliment Pharmacol Ther. 2003 Feb 15;17(4):503-8. doi: 10.1046/j.1365-2036.2003.01440.x. Aliment Pharmacol Ther. 2003. PMID: 12622758 Free article.
The direct use of 6-thioguanine may offer a more rapid and safer alternative. We conducted an open prospective study to investigate the efficacy and safety of 6-thioguanine in chronic active Crohn's disease. METHODS: : Thirty-seven patients with chroni …
The direct use of 6-thioguanine may offer a more rapid and safer alternative. We conducted an open prospective study to investigate t …
1,978 results
Jump to page
Feedback